A New Model of Care for Patients  with Thyroid Nodules
Learn how Afirma Thyroid FNA Analysis is reducing unnecessary surgeries, facilitating treatment decisions from a single FNA, and lowering healthcare costs. Visit Afirma.com.


Percepta Bronchial Genomic Classifier

Improving Lung Cancer Diagnosis
The Percepta Bronchial Genomic Classifier uses the power of genomics to identify patients at low risk for lung cancer and thus may reduce the need for invasive, risky, and costly diagnostic procedures. Learn more.

Veracyte is pioneering the field of molecular cytology to improve patient outcomes and lower healthcare costs. More on our pipeline.

Veracyte Sees Clinical Evidence, Medicare Coverage as Major MDx Success Factors
(Sep 9, 2016, GenomeWeb)

Veracyte Achieves Major Medicare Coverage Milestone for the Percepta® Classifier to Improve Lung Cancer Diagnosis
(Sept 8, 2016)

New Data Show That Veracyte’s Afirma® Gene Expression Classifier Reduces Unnecessary Thyroid Surgeries and Costs During Long-Term Follow-Up

(Mar 16, 2016)

Veracyte Announces Publication of Long-Term Clinical Utility Study for the Afirma® Gene Expression Classifier
(Jan 22, 2016)

Veracyte Announces Positive Coverage Policy for the Afirma® Gene Expression Classifier from Health Care Service Corporation (HCSC)

Additional Blues Plan Issues Positive Coverage Decision for the Afirma GEC; Two More Sign In-Network Contracts
(Dec 14, 2015)